Is Kratom the New 'Legal High' on the Block?: The Case of an Emerging Opioid Receptor Agonist with Substance Abuse Potential

Kratom is an unscheduled opioid receptor agonist that comes in the form of dietary supplements currently being abused by chronic pain patients on prescription opioids. Active alkaloids isolated from kratom such as mitragynine and 7-hydroxymitragynine are thought to act on mu- and delta-opioid recept...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pain physician 2017-01, Vol.20 (1), p.E195-E198
Hauptverfasser: Chang-Chien, George C, Odonkor, Charles A, Amorapanth, Prin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page E198
container_issue 1
container_start_page E195
container_title Pain physician
container_volume 20
creator Chang-Chien, George C
Odonkor, Charles A
Amorapanth, Prin
description Kratom is an unscheduled opioid receptor agonist that comes in the form of dietary supplements currently being abused by chronic pain patients on prescription opioids. Active alkaloids isolated from kratom such as mitragynine and 7-hydroxymitragynine are thought to act on mu- and delta-opioid receptors as well as alpha-2 adrenergic and 5-HT2A receptors. Animal studies suggest that kratom may be more potent than morphine. Consequently, kratom consumption produces analgesic and euphoric feelings among users. In particular, some chronic pain patients on opioids take kratom to counteract the effects of opioid withdrawal. Although the Food and Drug Administration has banned its use as a dietary supplement, kratom continues to be widely available and easily accessible on the Internet at much less expensive rates than some opioid replacement therapies like buprenorphine. There are no federal regulations monitoring the sale and distribution of this drug, yet kratom has been associated with severe signs and symptoms such as hallucinations, delusions, depressions, myalgias, chills, nausea/vomiting, respiratory hepatoxicity, seizures, coma, and death. A search of the pain literature shows past research has not described the use and potential deleterious effects of this drug. Many pain physicians are not familiar with kratom and as providers who take care of high-risk chronic pain patients using prescribed opioids, knowledge of current unregulated opioid receptor agonists with abuse potential is of paramount importance. The goal of this article is to introduce kratom to pain specialists and to spur a conversation on how pain physicians may take the lead to help curb the opioid abuse and overdose epidemic. Further studies may be required to help better understand the clinical and long-term effects of kratom use among chronic pain patients.Key words: Opioid receptor agonist, Kratom, Mitragynine, opioid overdose, chronic pain, substance abuse.
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1857752516</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1857752516</sourcerecordid><originalsourceid>FETCH-LOGICAL-p239t-d99b365c0f76a8c1a2c344fd08fda83026caa73786ac036b0c0dad19680a23c3</originalsourceid><addsrcrecordid>eNpdkN1LwzAUxYsobn78CxLwQV8K-VjS1BeZYzpxONG9l9s07TLbpDYpQ_CPt-h88eleLr9zOeccRGNKOI4JmaSH0ZhwxmJGeDqKTrzfYsxEmrLjaEQlTqgkdBx9PXr01EFwDQobjZ71Dl0tdQU1Wphqc4Wc_bnf1U69396g9bDPwGvkSgQWzRvdVcZWaNUaZwr0qpVug-vQtHLW-IB2JmzQW5_7AFZpNM37QfvigrbBQH0WHZVQe32-n6fR-n6-ni3i5erhcTZdxi1laYiLNM2Z4AqXiQCpCFDFJpOywLIsQDJMhQJIWCIFqCFijhUuoCCpkBgoU-w0uv5923buo9c-ZI3xStc1WO16nxHJk4RTTsSAXv5Dt67v7GAuo4ILTLiQdKAu9lSfN7rI2s400H1mf7Wybxk2csg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2656015682</pqid></control><display><type>article</type><title>Is Kratom the New 'Legal High' on the Block?: The Case of an Emerging Opioid Receptor Agonist with Substance Abuse Potential</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Chang-Chien, George C ; Odonkor, Charles A ; Amorapanth, Prin</creator><creatorcontrib>Chang-Chien, George C ; Odonkor, Charles A ; Amorapanth, Prin</creatorcontrib><description>Kratom is an unscheduled opioid receptor agonist that comes in the form of dietary supplements currently being abused by chronic pain patients on prescription opioids. Active alkaloids isolated from kratom such as mitragynine and 7-hydroxymitragynine are thought to act on mu- and delta-opioid receptors as well as alpha-2 adrenergic and 5-HT2A receptors. Animal studies suggest that kratom may be more potent than morphine. Consequently, kratom consumption produces analgesic and euphoric feelings among users. In particular, some chronic pain patients on opioids take kratom to counteract the effects of opioid withdrawal. Although the Food and Drug Administration has banned its use as a dietary supplement, kratom continues to be widely available and easily accessible on the Internet at much less expensive rates than some opioid replacement therapies like buprenorphine. There are no federal regulations monitoring the sale and distribution of this drug, yet kratom has been associated with severe signs and symptoms such as hallucinations, delusions, depressions, myalgias, chills, nausea/vomiting, respiratory hepatoxicity, seizures, coma, and death. A search of the pain literature shows past research has not described the use and potential deleterious effects of this drug. Many pain physicians are not familiar with kratom and as providers who take care of high-risk chronic pain patients using prescribed opioids, knowledge of current unregulated opioid receptor agonists with abuse potential is of paramount importance. The goal of this article is to introduce kratom to pain specialists and to spur a conversation on how pain physicians may take the lead to help curb the opioid abuse and overdose epidemic. Further studies may be required to help better understand the clinical and long-term effects of kratom use among chronic pain patients.Key words: Opioid receptor agonist, Kratom, Mitragynine, opioid overdose, chronic pain, substance abuse.</description><identifier>ISSN: 1533-3159</identifier><identifier>EISSN: 2150-1149</identifier><identifier>PMID: 28072812</identifier><language>eng</language><publisher>United States: American Society of Interventional Pain Physician</publisher><subject>Analgesics, Opioid - adverse effects ; Analgesics, Opioid - therapeutic use ; Animals ; Case reports ; Chronic pain ; Humans ; Narcotics ; Pain ; Receptors, Opioid - agonists ; Substance use disorder ; Substance Withdrawal Syndrome ; Substance-Related Disorders</subject><ispartof>Pain physician, 2017-01, Vol.20 (1), p.E195-E198</ispartof><rights>2017. This work is published under https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28072812$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chang-Chien, George C</creatorcontrib><creatorcontrib>Odonkor, Charles A</creatorcontrib><creatorcontrib>Amorapanth, Prin</creatorcontrib><title>Is Kratom the New 'Legal High' on the Block?: The Case of an Emerging Opioid Receptor Agonist with Substance Abuse Potential</title><title>Pain physician</title><addtitle>Pain Physician</addtitle><description>Kratom is an unscheduled opioid receptor agonist that comes in the form of dietary supplements currently being abused by chronic pain patients on prescription opioids. Active alkaloids isolated from kratom such as mitragynine and 7-hydroxymitragynine are thought to act on mu- and delta-opioid receptors as well as alpha-2 adrenergic and 5-HT2A receptors. Animal studies suggest that kratom may be more potent than morphine. Consequently, kratom consumption produces analgesic and euphoric feelings among users. In particular, some chronic pain patients on opioids take kratom to counteract the effects of opioid withdrawal. Although the Food and Drug Administration has banned its use as a dietary supplement, kratom continues to be widely available and easily accessible on the Internet at much less expensive rates than some opioid replacement therapies like buprenorphine. There are no federal regulations monitoring the sale and distribution of this drug, yet kratom has been associated with severe signs and symptoms such as hallucinations, delusions, depressions, myalgias, chills, nausea/vomiting, respiratory hepatoxicity, seizures, coma, and death. A search of the pain literature shows past research has not described the use and potential deleterious effects of this drug. Many pain physicians are not familiar with kratom and as providers who take care of high-risk chronic pain patients using prescribed opioids, knowledge of current unregulated opioid receptor agonists with abuse potential is of paramount importance. The goal of this article is to introduce kratom to pain specialists and to spur a conversation on how pain physicians may take the lead to help curb the opioid abuse and overdose epidemic. Further studies may be required to help better understand the clinical and long-term effects of kratom use among chronic pain patients.Key words: Opioid receptor agonist, Kratom, Mitragynine, opioid overdose, chronic pain, substance abuse.</description><subject>Analgesics, Opioid - adverse effects</subject><subject>Analgesics, Opioid - therapeutic use</subject><subject>Animals</subject><subject>Case reports</subject><subject>Chronic pain</subject><subject>Humans</subject><subject>Narcotics</subject><subject>Pain</subject><subject>Receptors, Opioid - agonists</subject><subject>Substance use disorder</subject><subject>Substance Withdrawal Syndrome</subject><subject>Substance-Related Disorders</subject><issn>1533-3159</issn><issn>2150-1149</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpdkN1LwzAUxYsobn78CxLwQV8K-VjS1BeZYzpxONG9l9s07TLbpDYpQ_CPt-h88eleLr9zOeccRGNKOI4JmaSH0ZhwxmJGeDqKTrzfYsxEmrLjaEQlTqgkdBx9PXr01EFwDQobjZ71Dl0tdQU1Wphqc4Wc_bnf1U69396g9bDPwGvkSgQWzRvdVcZWaNUaZwr0qpVug-vQtHLW-IB2JmzQW5_7AFZpNM37QfvigrbBQH0WHZVQe32-n6fR-n6-ni3i5erhcTZdxi1laYiLNM2Z4AqXiQCpCFDFJpOywLIsQDJMhQJIWCIFqCFijhUuoCCpkBgoU-w0uv5923buo9c-ZI3xStc1WO16nxHJk4RTTsSAXv5Dt67v7GAuo4ILTLiQdKAu9lSfN7rI2s400H1mf7Wybxk2csg</recordid><startdate>201701</startdate><enddate>201701</enddate><creator>Chang-Chien, George C</creator><creator>Odonkor, Charles A</creator><creator>Amorapanth, Prin</creator><general>American Society of Interventional Pain Physician</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>201701</creationdate><title>Is Kratom the New 'Legal High' on the Block?: The Case of an Emerging Opioid Receptor Agonist with Substance Abuse Potential</title><author>Chang-Chien, George C ; Odonkor, Charles A ; Amorapanth, Prin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p239t-d99b365c0f76a8c1a2c344fd08fda83026caa73786ac036b0c0dad19680a23c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Analgesics, Opioid - adverse effects</topic><topic>Analgesics, Opioid - therapeutic use</topic><topic>Animals</topic><topic>Case reports</topic><topic>Chronic pain</topic><topic>Humans</topic><topic>Narcotics</topic><topic>Pain</topic><topic>Receptors, Opioid - agonists</topic><topic>Substance use disorder</topic><topic>Substance Withdrawal Syndrome</topic><topic>Substance-Related Disorders</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chang-Chien, George C</creatorcontrib><creatorcontrib>Odonkor, Charles A</creatorcontrib><creatorcontrib>Amorapanth, Prin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Pain physician</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chang-Chien, George C</au><au>Odonkor, Charles A</au><au>Amorapanth, Prin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Is Kratom the New 'Legal High' on the Block?: The Case of an Emerging Opioid Receptor Agonist with Substance Abuse Potential</atitle><jtitle>Pain physician</jtitle><addtitle>Pain Physician</addtitle><date>2017-01</date><risdate>2017</risdate><volume>20</volume><issue>1</issue><spage>E195</spage><epage>E198</epage><pages>E195-E198</pages><issn>1533-3159</issn><eissn>2150-1149</eissn><abstract>Kratom is an unscheduled opioid receptor agonist that comes in the form of dietary supplements currently being abused by chronic pain patients on prescription opioids. Active alkaloids isolated from kratom such as mitragynine and 7-hydroxymitragynine are thought to act on mu- and delta-opioid receptors as well as alpha-2 adrenergic and 5-HT2A receptors. Animal studies suggest that kratom may be more potent than morphine. Consequently, kratom consumption produces analgesic and euphoric feelings among users. In particular, some chronic pain patients on opioids take kratom to counteract the effects of opioid withdrawal. Although the Food and Drug Administration has banned its use as a dietary supplement, kratom continues to be widely available and easily accessible on the Internet at much less expensive rates than some opioid replacement therapies like buprenorphine. There are no federal regulations monitoring the sale and distribution of this drug, yet kratom has been associated with severe signs and symptoms such as hallucinations, delusions, depressions, myalgias, chills, nausea/vomiting, respiratory hepatoxicity, seizures, coma, and death. A search of the pain literature shows past research has not described the use and potential deleterious effects of this drug. Many pain physicians are not familiar with kratom and as providers who take care of high-risk chronic pain patients using prescribed opioids, knowledge of current unregulated opioid receptor agonists with abuse potential is of paramount importance. The goal of this article is to introduce kratom to pain specialists and to spur a conversation on how pain physicians may take the lead to help curb the opioid abuse and overdose epidemic. Further studies may be required to help better understand the clinical and long-term effects of kratom use among chronic pain patients.Key words: Opioid receptor agonist, Kratom, Mitragynine, opioid overdose, chronic pain, substance abuse.</abstract><cop>United States</cop><pub>American Society of Interventional Pain Physician</pub><pmid>28072812</pmid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1533-3159
ispartof Pain physician, 2017-01, Vol.20 (1), p.E195-E198
issn 1533-3159
2150-1149
language eng
recordid cdi_proquest_miscellaneous_1857752516
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Analgesics, Opioid - adverse effects
Analgesics, Opioid - therapeutic use
Animals
Case reports
Chronic pain
Humans
Narcotics
Pain
Receptors, Opioid - agonists
Substance use disorder
Substance Withdrawal Syndrome
Substance-Related Disorders
title Is Kratom the New 'Legal High' on the Block?: The Case of an Emerging Opioid Receptor Agonist with Substance Abuse Potential
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T21%3A06%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Is%20Kratom%20the%20New%20'Legal%20High'%20on%20the%20Block?:%20The%20Case%20of%20an%20Emerging%20Opioid%20Receptor%20Agonist%20with%20Substance%20Abuse%20Potential&rft.jtitle=Pain%20physician&rft.au=Chang-Chien,%20George%20C&rft.date=2017-01&rft.volume=20&rft.issue=1&rft.spage=E195&rft.epage=E198&rft.pages=E195-E198&rft.issn=1533-3159&rft.eissn=2150-1149&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1857752516%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2656015682&rft_id=info:pmid/28072812&rfr_iscdi=true